 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Idebenone
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Role in Alzheimer's Disease:
|
Improve cognitive and non-cognitive symptoms in
mild/moderate AD. Protect cells from beta amyloid induced
oxidative stress.
|
|
Pharmacological Role:
|
A benzoquinone derivative, it is hypothesized to improve
brain metabolism and protect cell membranes against lipid
peroxidation. It also promotes secretion of nerve growth
factor (NGF).
|
|
Side Effects:
|
All mild, relative to placebo-receiving groups: nausea,
increased hepatic enzymes, headache, dizziness, bronchitis.
|
|
Evidence pro its efficacy:
|
Tested up to twelve months in (one of) two multicenter,
randomized, double-blinded studies. These studies indicate
significant, dose-dependent improvements in cognitive and
behavioral symptoms.
|
|
Dosage:
|
90 mg/day
|
|
Companies:
|
Takeda Chemical Industries
|
Gutzmann H, Kuhl KP, Hadler D, Rapp MA. Safety and
efficacy of idebenone versus tacrine in patients with
Alzheimer's disease: results of a randomized, double-
blind, parallel-group multicenter study.
Pharmacopsychiatry. 2002 Jan;35(1):12-8. Abstract
Pereira C, Santos MS, Oliveira C. Involvement of oxidative
stress on the impairment of energy metabolism induced by A
beta peptides on PC12 cells: protection by antioxidants.
Neurobiol Dis. 1999 Jun;6(3):209-19. Abstract
Gutzmann H, Hadler D. Sustained efficacy and safety of
idebenone in the treatment of Alzheimer's disease: update
on a 2-year double-blind multicentre study. J Neural
Transm Suppl. 1998;54:301-10. Abstract
Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M,
Kameyama T, Furukawa Y, Hayashi K, Nabeshima T. Orally
active NGF synthesis stimulators: potential therapeutic
agents in Alzheimer's disease. Behav Brain Res. 1997 Feb;83
(1-2):117-22. Abstract
Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM.
A controlled study of 2 doses of idebenone in the
treatment of Alzheimer's disease. Neuropsychobiology.
1997;36(2):73-82. Abstract
Bergamasco B, Scarzella L, La Commare P. Idebenone, a new
drug in the treatment of cognitive impairment in patients
with dementia of the Alzheimer type. Funct Neurol. 1994
May-Jun;9(3):161-8. Abstract
|
|
|
|
|
Home
